Wednesday, June 27, 2018 12:08:56 PM
The bull case on GALT is simply stated in this manner:
1.) The FDA has allowed them to go to Phase three on the strength of a portion of the data from their Phase II test where the top line was missed. But about half the population of patients (those without esophegal varices) did respond well to the drug and that is what the Phase III study will test.
2.) They are the first late stage NASH drug to go ahead to phase III. The competitors in this portion of the NASH market are about 2 years behind them.
3.) Due to the large size of the NASH market and GALT's likely getting a drug on the market first, big pharma likely is interested in partnering or buying the company.
4.) The company hired advisors to shop itself to big pharma and BMY has already indicated interest in buying or partnering in the NASH arena.
5.) They also have a cancer indication in phase I tests that appears to supercharge Keytruda. Further test results on this should be out soon.
6.) The market cap of the company is tiny and any deal done with big pharma could yield a stock price much, much higher than the current one.
7.) The chairmen of the board is a billionaire who gave the company some really attractive terms for financing earlier this year so it has plenty of financial room for maneuver.
8.) The company instituted Transaction Bonuses that end at the end of 2018. If a transaction (partnership or sale of the company) is attained, key management personnel can get paid a bonus equal to 3X their annual compensation. These bonuses peak at a transaction valued at $1.5 billion.
9.) GALT's drug seems to be effective at cleaning up fibrosis, wherever it occurs. They just added a patent for Pulmonary fibrosis. If big pharma is convinced its positive impact on fibrosis is real that means there are lots of other big money possible indications for GALT.
10.) A board member made a small purchase of the stock this week.
The bear case is simply stated as follows:
1.) The CEO quit in early June, right after the new chairman and vice chairman of the board seemingly took charge of selling the company. He is a notable scientist in this field and his loss has to be felt at several levels. And why in the world did he quit? What does he know that we wish we knew?
2.) There has been a lot of insider selling related to 12b-5 plans that allow insiders to sell at predetermined levels despite any insider trading restrictions that might normally keep them from selling. These sales were put in place int he late February/early March time frame and triggered for different executives and board members during June as the share price ran higher on the back of transaction bonus and financial adviser hiring news. Not all insiders put such plans in place and neither the new billionaire chairman or the vice chairman have sold any shares. The vice chairman actually bought shares back in February. But for those that did sell, why were they willing to sell at these prices when they set these plans up earlier this year? While the FDA had not given the go ahead to go to Phase III yet, there really was not any other noteworthy info back then that we do not have right now.
3.) Last week the CFO sold half of his remaining holdings for nearly $2 million. These were normal sales not ones predetermined at certain price levels back in late February/early March via 12b-5 plans. Why would he sell if he thought an attractive transaction was a high likelihood?
4.) Will the ex CEO exercise his options on about 1.7 million shares and sell them prior to the end of the 90 days he has after leaving the company to do so?
5.) Will the fact that GALT is furthest along in the FDA testing process and that it is treating NASH after it is actually a real medical issue for a patient, rather than before like most of the other NASH companies, make it more attractive to big pharma or are there other aspects to the medical side of the equation that make GALT's approach less attractive relative to the competition. Some suggest that a carbohydrate based drug is not as likely to be approved by the FDA.
6.) GALT has had a sketchy history of communications with the market leading long term observers to be wary of what it says.
Recent GALT News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 12:00:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2024 12:08:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 11:55:19 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 11:50:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 12:41:21 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 12:38:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 11:50:32 AM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 07/23/2024 01:43:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/23/2024 01:38:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/20/2024 05:55:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 11:55:18 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 11:50:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 05:50:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:55:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:53:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:52:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:51:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:50:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:48:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:47:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:46:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:44:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:43:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:40:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2024 04:23:48 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM